CD163 and ductal breast carcinoma in situ: The comparison of the scores of stromal immune cells in 30 patients with primary DCIS and its invasive recurrence revealed an increased level of stromal CD20 + lymphocytes B and CD163 + macrophages M2 in invasive breast cancer what is consistent with results reported by other authors.